POXEL Poxel S.A.
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic pathophysiology, type 2 diabetes, and liver diseases. It also develops treatments for rare metabolic diseases and associated steatohepatitis to metabolic dysfunction. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial dysfunction; and Sumitomo Pharma for development and commercialization of Imeglimin. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.…
Industry Peers
BiotechnologyKey Statistics
About Poxel (EPA: POXEL)
›
Poxel (EPA: POXEL) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 5 employees.
The shares were at 0.1370 EUR on 19 November 2026, down 40.4% over 52 weeks. Its 52-week range is 0.1302 EUR to 0.4800 EUR: the price is 71.5% below the high and 5.2% above the low.
Its market capitalisation is 9.17M EUR.
Poxel reports an operating margin of -22.9% and revenue up 87.9% year over year.
Its debt exceeds its cash by 59.95M EUR. Its Piotroski F-score is 0 out of 9, a weak reading of its financial health.